CLINICAL TRIALS PROFILE FOR PIMODIVIR
✉ Email this page to a colleague
Clinical Trials for Pimodivir
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03376321 ↗ | A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection | Terminated | Janssen Research & Development, LLC | Phase 3 | The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment. |
| NCT03381196 ↗ | A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications | Terminated | Janssen Research & Development, LLC | Phase 3 | The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment. |
| NCT03768609 ↗ | A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults | Completed | Janssen-Cilag International NV | Phase 1 | The purpose of this study is to evaluate the effect of a single oral dose of cyclosporine on the pharmacokinetics of a single oral dose of pimodivir when coadministered to healthy adult participants under fasted conditions. |
| NCT03816631 ↗ | A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment | Completed | Janssen-Cilag International NV | Phase 1 | The purpose is to evaluate the pharmacokinetics (PK) of a single oral dose of 600 milligram (mg) pimodivir in adult participants with impaired hepatic function compared to adult participants with normal hepatic function. |
| NCT03947814 ↗ | A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment | Terminated | Janssen-Cilag International NV | Phase 1 | The purpose of this study is to evaluate the pharmacokinetics (PK) of pimodivir after a single oral dose of 600 milligrams (mg) in adult participants with severe renal impairment who are not on dialysis and in adult participants with end-stage renal disease (ESRD) who are not yet on dialysis compared to adult participants with normal renal function (Part A). Optionally, to evaluate the PK in adult participants with mild and/or moderate renal impairment compared to adult participants with normal renal function (Part B). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Pimodivir
Condition Name
Clinical Trial Locations for Pimodivir
Trials by Country
Clinical Trial Progress for Pimodivir
Clinical Trial Phase
Clinical Trial Sponsors for Pimodivir
Sponsor Name
